Neuropsychological Profiles and Trajectories in Preclinical Alzheimer's Disease

被引:36
|
作者
Ho, Jean K. [1 ]
Nation, Daniel A. [1 ]
机构
[1] Univ Southern Calif, Dept Psychol, 3620 South McClintock Ave, Los Angeles, CA 90089 USA
基金
美国国家卫生研究院; 加拿大健康研究院;
关键词
Alzheimer's disease; Amyloid beta; Tau; Biomarkers; Cognition; Memory; MILD COGNITIVE IMPAIRMENT; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; RISK-FACTOR; DECLINE; PATHOPHYSIOLOGY; RECOMMENDATIONS; NEURODEGENERATION; INDIVIDUALS;
D O I
10.1017/S135561771800022X
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: The present study investigated the independent and synergistic effects of amyloid beta (A beta(1-42)) and phosphorylated tau (Ptau) pathologies on neuropsychological profiles and trajectories in cognitively normal older adults. Methods: Alzheimer's Disease Neuroimaging Initiative participants identified as cognitively normal at baseline underwent longitudinal assessment (N= 518; 0, 12, 24, 36 months), baseline lumbar puncture and follow-up cognitive exams. Cerebral spinal fluid (CSF) biomarker profiles (A beta-Ptau-, A beta+Ptau-, A beta-Ptau+, A beta+Ptau+) were compared on baseline profiles and trajectories for memory (Rey Auditory Verbal Learning Test), attention/executive function (Trail Making Test, A and B), language (Animal Fluency, Vegetable Fluency, Boston Naming Test) and processing speed (Digit Symbol) using multilevel models. Results: The A beta+Ptau+ group exhibited significantly worse baseline performance on tests of memory and executive function relative to the A beta-Ptau+ and A beta-Ptau- groups. The A beta+Ptau- group fell between the A beta+Ptau+ participants and the A beta-Ptau- and A beta-Ptau+ groups on all three cognitive domains and exhibited worse baseline executive function. The A beta-Ptau+ group performed worse than A beta-Ptau- participants on processing speed. Over 36-month follow-up, the A beta+Ptau+ group exhibited the greatest declines in memory and semantic fluency compared to all other groups. Conclusions: Cognitively normal older adults with both A beta and Ptau pathology exhibited the weakest profile, marked by the worst memory decline compared to the other groups. Other subtle changes in this group included declines in executive function and semantic fluency. Those with Ptau pathology alone showed slowed processing speed, and those with A beta pathology alone showed worse attention and executive function compared to biomarker negative participants.
引用
收藏
页码:693 / 702
页数:10
相关论文
共 50 条
  • [1] Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease
    Twamley, Elizabeth W.
    Ropacki, Susan A. Legendre
    Bondi, Mark W.
    JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 2006, 12 (05) : 707 - 735
  • [2] Neuropsychological assessment in preclinical and prodromal Alzheimer's disease
    Nikolai, Tomas
    INTERNATIONAL JOURNAL OF PSYCHOLOGY, 2024, 59 : 453 - 453
  • [3] Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease
    Yakoub, Yara J.
    Ashton, Nicholas
    Strikwerda-Brown, Cherie
    Montoliu-Gaya, Laia K.
    Karikari, Thomas
    Kac, Przemyslaw R.
    Gonzalez-Ortiz, Fernando
    Gallego-Rudolf, Jonathan
    Meyer, Pierre-Francois
    St-Onge, Frederic
    Schoell, Michael
    Soucy, Jean-Paul
    Breitner, John C. S.
    Zetterberg, Henrik
    Blennow, Kaj
    Poirier, Judes
    Villeneuve, Sylvia
    ALZHEIMERS & DEMENTIA, 2023, : 5620 - 5631
  • [4] Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease
    Arnáiz, E
    Almkvist, O
    ACTA NEUROLOGICA SCANDINAVICA, 2003, 107 : 34 - 41
  • [5] Alcohol, dementia, and Alzheimer's disease: Comparison of neuropsychological profiles
    Saxton, J
    Munro, CA
    Butters, MA
    Schramke, C
    McNeil, MA
    JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, 2000, 13 (03) : 141 - 149
  • [6] Neuropsychological features of early Alzheimer's disease: Preclinical and clinical stages
    Almkvist, O
    ACTA NEUROLOGICA SCANDINAVICA, 1996, 93 : 63 - 71
  • [7] Detecting dementia: Novel neuropsychological markers of preclinical Alzheimer's disease
    Blackwell, AD
    Sahakian, BJ
    Vesey, R
    Semple, JM
    Robbins, TW
    Hodges, JR
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2004, 17 (1-2) : 42 - 48
  • [8] Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease
    Li, Xiaohang
    Tsolis, Konstantinos C.
    Koper, Marta J.
    Ronisz, Alicja
    Ospitalieri, Simona
    von Arnim, Christine A. F.
    Vandenberghe, Rik
    Tousseyn, Thomas
    Scheuerle, Angelika
    Economou, Anastassios
    Carpentier, Sebastien
    Otto, Markus
    Thal, Dietmar Rudolf
    ALZHEIMERS & DEMENTIA, 2021, 17 (06) : 946 - 958
  • [9] Preclinical Cognitive Trajectories Differ for Alzheimer's Disease and Vascular Dementia
    Laukka, Erika J.
    MacDonald, Stuart W. S.
    Fratiglioni, Laura
    Backman, Lars
    JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 2012, 18 (02) : 191 - 199
  • [10] Awareness for People With Alzheimer's Disease: Profiles and Weekly Trajectories
    Mayelle, Amandine
    Hazebrouck, Capucine
    El Haj, Mohamad
    Mograbi, Daniel C.
    Antoine, Pascal
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 13